Idarucizumab: What Should We Know?

Author(s): Francesca Cortese*, Giacinto Calculli, Michele Gesualdo, Annagrazia Cecere, Annapaola Zito, Fiorella De Vito, Rossella Carbonara, Santa Carbonara, Anna Maria Cortese, Marco Matteo Ciccone.

Journal Name: Current Drug Targets

Volume 19 , Issue 1 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Background: Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis. Moreover, it can also be applied to reverse the dabigatran anticoagulant activity in emergency surgery or in other invasive procedure at high risk of bleeding.

Objective: In this study, we discuss idarucizumab in light of the available literature data by conducting extensive research in the PubMed, EMBASE and Cochrane Library on the topic, using idarucizumab, dabigatran and their combinations as Mesh terms, and focusing on high impact investigations.

Results: Several studies have demonstrated the capacity of idarucizumab to reverse laboratory measures of dabigatran-associated coagulopathy, however its efficacy and safety in real world patients are still not very clear because of the scarcity of available data which should be assessed with an extensive post market surveillance.

Conclusion: The introduction of idarucizumab as dabigatran antidote in clinical practice represents a useful tool for clinicians. The possibility to rapidly restore the anticoagulation activity of dabigatran makes its use simpler and more manageable.

Keywords: Idarucizumab, dabigatran, antidote, anticoagulant activity, bleeding, anticogulant drugs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [81 - 88]
Pages: 8
DOI: 10.2174/1389450118666170925155943
Price: $65

Article Metrics

PDF: 27
PRC: 1